BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33939112)

  • 1. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
    Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
    Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
    Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
    Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
    Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
    PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
    Ding X; Sharko AC; McDermott MSJ; Schools GP; Chumanevich A; Ji H; Li J; Zhang L; Mack ZT; Sikirzhytski V; Shtutman M; Ivers L; O'Donovan N; Crown J; Győrffy B; Chen M; Roninson IB; Broude EV
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2201073119. PubMed ID: 35914167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
    Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
    Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
    Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
    Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
    Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
    Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
    Chen S; Li X; Feng J; Chang Y; Wang Z; Wen A
    Med Hypotheses; 2011 Aug; 77(2):206-8. PubMed ID: 21570197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
    Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
    Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and identification of small molecule inhibitors of ErbB2-induced invasion.
    Brix DM; Rafn B; Bundgaard Clemmensen K; Andersen SH; Ambartsumian N; Jäättelä M; Kallunki T
    Mol Oncol; 2014 Dec; 8(8):1703-18. PubMed ID: 25070180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
    Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.